Table 1.
Peptide | HLA | IgG† | CD4+INF‐γ+ ‡ | CD8+INF‐γ+ ‡ |
---|---|---|---|---|
Positive (%) | ||||
Lck33–47 | DR | 34 | 50 | 75 |
Lck37–47 | A2 | 6 | 75 | 25 |
Lck175–189 | DR | 44 | 25 | 75 |
Lck177–186 | A2 | 38 | 50 | 75 |
Lck190–204 | DR | 50 | 25 | 75 |
Lck194–204 | A2 | 59 | 25 | 75 |
Lck242–256 | DR | 44 | 50 | 25 |
Lck246–254 | A2 | 50 | 25 | 75 |
Lck289–303 | DR | 47 | 50 | 50 |
Lck290–298 | A2 | 22 | 25 | 75 |
Lck374–388 | DR | 34 | 25 | 50 |
Lck375–383 | A2 | 34 | 50 | 75 |
Lck377–384 | A2 | 16 | 75 | 50 |
Lck414–428 | DR | 63 | 50 | 50 |
Lck415–423 | A2 | 16 | 50 | 75 |
Lck487–501 | DR | 47 | 75 | 50 |
Lck489–497 | A2 | 63 | 50 | 75 |
†Positive percentages among the 32 patients are shown. ‡Positive percentages among four patients are shown.